Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic and genomic tumor testing and precision medicine, and INTERLINK Care Management, Inc. announced ...

Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic and tumor genomic testing and precision medicine, announced that the United States Patent and ...

Myriad Genetics, Inc. (MYGN), a genetic and genomic tumor testing and precision medicine provider, and INTERLINK Care Management, ...

SALT LAKE CITY, Feb. 06, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic and genomic tumor testing and precision medicine, and INTERLINK Care Management, Inc.

SALT LAKE CITY - Myriad Genetics , Inc. (NASDAQ: NASDAQ:MYGN), a company specializing in genetic testing and precision medicine with annual revenues of $824 million, has announced the issuance of two ...

Myriad Genetics (NASDAQ:MYGN – Get Free Report) had its target price cut by analysts at Piper Sandler from $24.00 to $14.00 in a research note issued on Thursday,Benzinga reports. The brokerage ...

Myriad Genetics, Inc. (NASDAQ:MYGN ... This collaboration allows physicians to order Myriad’s MyRisk Hereditary Cancer Test ...

Myriad Genetics launches an online prenatal genetic testing resource, the Know More Sooner website, to provide comprehensive information about reproductive and prenatal genetic testing.

Research analysts at Leerink Partnrs boosted their FY2024 EPS estimates for Myriad Genetics in a note issued to investors on Tuesday, January 21st. Leerink Partnrs analyst P. Souda now forecasts that ...

SALT LAKE CITY, Jan. 23, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, has launched a new educational website providing ...

Myriad Genetics, Inc. (NASDAQ ... This collaboration allows physicians to order Myriad’s MyRisk Hereditary Cancer Test and view the results of the test directly in Flatiron’s cloud-based ...